Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR Sublingual Immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Trial Profile

A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR Sublingual Immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Mar 2016 Pooled analysis of 4 trials (n=891), including this study and 3 other studies [see CTP 700020053, 700039691, 700040181] was presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Sep 2012 Results from an analysis of asthma status on outcomes presented at the 22nd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top